Operating Income (Loss) in USD of RELMADA THERAPEUTICS, INC. from Q1 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Relmada Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2012 to Q3 2025.
  • Relmada Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$10.3M, a 55.1% increase year-over-year.
  • Relmada Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$57.8M, a 36.9% increase year-over-year.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$83.9M, a 19.1% increase from 2023.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$104M, a 35.7% increase from 2022.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$161M, a 28.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$57.8M -$10.3M +$12.7M +55.1% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$70.5M -$10.2M +$8.6M +45.7% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$79.1M -$18.2M +$4.77M +20.7% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 -$83.9M -$19.1M +$7.75M +28.9% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025
Q3 2024 -$91.6M -$23M -$316K -1.39% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$91.3M -$18.8M +$7.21M +27.7% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$98.5M -$23M +$5.17M +18.3% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 -$104M -$26.8M +$11.9M +30.7% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025
Q3 2023 -$116M -$22.7M +$16M +41.4% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$132M -$26M +$19.5M +42.8% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$151M -$28.2M +$10.1M +26.5% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 -$161M -$38.7M -$4.52M -13.2% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024
Q3 2022 -$157M -$38.7M +$3.92M +9.18% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$161M -$45.5M -$19.1M -72% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 -$142M -$38.3M -$15.9M -70.9% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2022
Q4 2021 -$126M -$34.2M -$13.3M -63.4% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023
Q3 2021 -$112M -$42.7M -$25.5M -148% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$87M -$26.5M -$13.7M -107% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$73.3M -$22.4M -$12.4M -125% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$60.8M -$20.9M -$16.4M -358% 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 -$44.5M -$17.2M -$13.5M -363% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$31M -$12.8M -$8.62M -208% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021
Q1 2020 -$22.4M -$9.97M -$7.27M -269% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q4 2019 -$15.1M -$4.56M -$1.09M -31.2% 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021
Q3 2019 -$14M -$3.71M -$1.3M -53.8% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 -$12.7M -$4.14M -$2.21M -114% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$10.5M -$2.7M -$152K -5.97% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$10.4M -$3.48M -$2.02M -139% 01 Oct 2018 31 Dec 2018 10-Q 13 Feb 2019
Q3 2018 -$8.35M -$2.41M -$1.43M -146% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$6.92M -$1.93M -$147K -8.26% 01 Apr 2018 30 Jun 2018 10-KT 26 Mar 2020
Q1 2018 -$6.77M -$2.55M -$267K -11.7% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$6.5M -$1.46M +$79.8K +5.2% 01 Oct 2017 31 Dec 2017 10-Q 13 Feb 2019
Q3 2017 -$6.58M -$981K +$636K +39.3% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$7.22M -$1.78M +$1.33M +42.8% 01 Apr 2017 30 Jun 2017 10-K 28 Sep 2018
Q1 2017 -$8.55M -$2.28M +$464K +16.9% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$9.02M -$1.54M +$4.19M +73.2% 01 Oct 2016 31 Dec 2016 10-Q 12 Feb 2018
Q3 2016 -$13.2M -$1.62M +$3.01M +65.1% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 -$16.2M -$3.12M +$1.3M +29.4% 01 Apr 2016 30 Jun 2016 10-K 28 Sep 2017
Q1 2016 -$17.5M -$2.75M +$1.83M +40% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 -$19.3M -$5.72M -$1.34M -30.5% 01 Oct 2015 31 Dec 2015 10-Q 10 Feb 2017
Q3 2015 -$18M -$4.63M -$907K -24.4% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 -$17.1M -$4.41M 01 Apr 2015 30 Jun 2015 10-K 09 Sep 2016
Q1 2015 -$4.58M -$3.87M -543% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 -$4.38M +$670K +13.3% 01 Oct 2014 31 Dec 2014 10-Q 05 Feb 2016
Q3 2014 -$3.72M -$3.24M -673% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q1 2014 -$6.27M -$712K -$111K -18.5% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$6.16M -$5.06M -$5.05M 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015
Q3 2013 -$1.11M -$482K 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014
Q2 2013 -$19.5K -$17K 01 Mar 2013 31 May 2013 10-Q 12 Jul 2013
Q1 2013 -$601K -$600K 01 Jan 2013 31 Mar 2013 8-K 27 May 2014
Q4 2012 -$9.02K* 01 Sep 2012 30 Nov 2012 10-Q 13 Jan 2014
Q2 2012 -$2.48K* 01 Mar 2012 31 May 2012 10-Q 12 Jul 2013
Q1 2012 -$503* 01 Dec 2011 29 Feb 2012 10-Q 03 May 2013

RELMADA THERAPEUTICS, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$83.9M +$19.8M +19.1% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$104M +$57.5M +35.7% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 -$161M -$35.5M -28.3% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 -$126M -$64.9M -107% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 -$60.8M -$45.7M -303% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 -$15.1M -$8.19M -118% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 -$6.92M +$301K +4.18% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 -$7.22M +$9M +55.5% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
2016 -$16.2M +$884K +5.17% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 -$17.1M 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016
2013 -$6.77M -$3.62M -115% 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015
2012 -$3.16M 01 Jan 2012 31 Dec 2012 10-KT 09 Sep 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.